ID: ALA3397806

Max Phase: Preclinical

Molecular Formula: C26H25F2NO4

Molecular Weight: 453.49

Molecule Type: Small molecule

Representations

Canonical SMILES:  O[C@@H]1C[C@@H](C(c2ccc(F)cc2)c2ccc(F)cc2)OC[C@H]1NCc1ccc2c(c1)OCO2

Standard InChI:  InChI=1S/C26H25F2NO4/c27-19-6-2-17(3-7-19)26(18-4-8-20(28)9-5-18)25-12-22(30)21(14-31-25)29-13-16-1-10-23-24(11-16)33-15-32-23/h1-11,21-22,25-26,29-30H,12-15H2/t21-,22-,25+/m1/s1

Standard InChI Key:  WZJTUSKNBWEOJQ-RQTOMXEWSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 453.49

Molecular Weight (Monoisotopic): 453.1752

AlogP: 4.13

#Rotatable Bonds: 6

Polar Surface Area: 59.95

Molecular Species: NEUTRAL

HBA: 5

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 8.18

CX LogP: 4.28

CX LogD: 3.43

Aromatic Rings: 3

Heavy Atoms: 33

QED Weighted: 0.59

Np Likeness Score: 0.13

References

1. Santra S, Sharma H, Vedachalam S, Antonio T, Reith M, Dutta A..  (2015)  Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template.,  23  (4): [PMID:25593099] [10.1016/j.bmc.2014.12.040]

Source

Source(1):

• Scientific Literature